PPARγ信号通路介导巨噬细胞参与动脉粥样硬化发生的研究进展

doi:10.3969/j.issn.1004-616x.2026.01.014

摘要/Abstract

摘要： 动脉粥样硬化是一种以脂质异常沉积和慢性炎症为特征的慢性血管疾病，巨噬细胞在其进展中起核心作用。过氧化物酶体增殖物激活受体γ(PPARγ)是核受体超家族的关键转录因子，除调控脂肪酸代谢与糖脂平衡外，近年来被发现通过介导巨噬细胞参与调节脂质代谢、抑制炎症反应、驱动M2型抗炎极化、影响血管内皮细胞功能和抑制平滑肌细胞增殖或迁移等，对心血管系统有着保护性作用。本文聚焦PPARγ信号通路调控巨噬细胞功能的最新研究进展，系统阐述其在动脉粥样硬化防治中的作用。

关键词: 动脉粥样硬化, 巨噬细胞, 过氧化物酶体增殖物激活受体, 信号通路, PPARγ

中图分类号:

Q291

马堰晖, 马春艳, 明程远, 杨玉, 吕广鑫. PPARγ信号通路介导巨噬细胞参与动脉粥样硬化发生的研究进展[J]. 癌变·畸变·突变, 2026, 38(1): 79-81,84.

参考文献

[1] KONG P, CUI Z Y, HUANG X F, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention [J]. Signal Transduct Target Ther, 2022, 7(1): 131.
[2] RUIZ-LEóN A M, LAPUENTE M, ESTRUCH R, et al. Clinical advances in immunonutrition and atherosclerosis: a review[J]. Front Immunol, 2019, 10: 837.
[3] BLAGOV A V, MARKIN A M, BOGATYREVA A I, et al. The role of macrophages in the pathogenesis of atherosclerosis[J]. Cells, 2023, 12(4): 522.
[4] 杨艳, 周禹, 隗雅姿, 等. PPARγ在自身免疫性疾病中的研究进展[J]. 药学学报, 2022, 57(10): 3124-3132.
[5] SOBOLEV V V, TCHEPOURINA E, KORSUNSKAYA I M, et al. The role of transcription factor PPAR-γ in the pathogenesis of psoriasis, skin cells, and immune cells[J]. Int J Mol Sci, 2022, 23(17): 9708.
[6] CHANDRA M, MIRIYALA S, PANCHATCHARAM M. PPARγand its role in cardiovascular diseases[J]. PPAR Res, 2017, 2017: 6404638.
[7] QIU Y H, GAN M L, WANG X Y, et al. The global perspective on peroxisome proliferator-activated receptor γ (PPARγ) in ectopic fat deposition: a review[J]. Int J Biol Macromol, 2023, 253(Pt 5): 127042.
[8] LIU L, ZHOU Y, LIU Z M, et al. Osr1 regulates macrophage-mediated liver inflammation in nonalcoholic fatty liver disease progression[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(5): 1117-1133.
[9] GHODSIAN N, YEANDLE A, HOCK B D, et al. CD36 down regulation by the macrophage antioxidant 7, 8-dihydroneopterin through modulation of PPAR-γ activity[J]. Free Radic Res, 2022, 56(5/6): 366-377.
[10] 毛晓娜, 杜俊蓉, 旷喜, 等. PPARγ激动剂藁本内酯的中枢抗炎作用及机制研究[J]. 中药药理与临床, 2017, 33(1): 26-30.
[11] ZHU T, ZHANG W, FENG S J, et al. Emodin suppresses LPS-induced inflammation in RAW264.7 cells through a PPARγ-dependent pathway[J]. Int Immunopharmacol, 2016, 34: 16-24.
[12] LI T, WANG W, LI Y X, et al. Pseudolaric acid B attenuates atherosclerosis progression and inflammation by suppressing PPARγ-mediated NF-κB activation[J]. Int Immunopharmacol, 2018, 59: 76-85.
[13] YANG X F, SHANG D J. The role of peroxisome proliferator-activated receptor γ in lipid metabolism and inflammation in atherosclerosis[J]. Cell Biol Int, 2023, 47(9): 1469-1487.
[14] ZHENG S S, HUANG H, LI Y Z, et al. Yin-Xing-Tong-Mai decoction attenuates atherosclerosis via activating PPARγ-LXRα-ABCA1/ABCG1 pathway[J]. Pharmacol Res, 2021, 169: 105639.
[15] ZHANG M, HOU L J, TANG W Y, et al. Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling[J]. J Cell Mol Med, 2023, 27(24): 4155-4170.
[16] TABAS I, BORNFELDT K E. Macrophage phenotype and function in different stages of atherosclerosis[J]. Circ Res, 2016, 118(4): 653-667.
[17] ZHANG Y, SHI X J, HAN J L, et al. Convallatoxin promotes M2 macrophage polarization to attenuate atherosclerosis through PPARγ-integrin α(v)β(5) signaling pathway[J]. Drug Des Devel Ther, 2021, 15: 803-812.
[18] 宋玮, 张钟艺, 王楷, 等. 茱萸丸通过PPARγ/NF-κB信号通路促进巨噬细胞M2型极化防治动脉粥样硬化[J]. 中国中药杂志, 2024, 49(1): 243-250.
[19] RAPOSEIRAS ROUBíN S, CORDERO A. The two-way relationship between cancer and atherosclerosis[J]. Rev Esp Cardiol (Engl Ed), 2019, 72(6): 487-494.
[20] HALL A E, JADE D, SHAIK F, et al. Modified lipid particle recognition: a link between atherosclerosis and cancer?[J]. Biology, 2025, 14(6): 675.
[21] KATSI V, PAPAKONSTANTINOU I, TSIOUFIS K. Atherosclerosis, diabetes mellitus, and cancer: common epidemiology, shared mechanisms, and future management[J]. Int J Mol Sci, 2023, 24(14): 11786.
[22] TAPIA-VIEYRA J V, DELGADO-COELLO B, MAS-OLIVA J. Atherosclerosis and cancer；a resemblance with far-reaching implications[J]. Arch Med Res, 2017, 48(1): 12-26.
[23] BALZAN S, LUBRANO V. LOX-1 receptor: a potential link in atherosclerosis and cancer[J]. Life Sci, 2018, 198: 79-86.
[24] ZHANG F Y, WANG L, CHEN Q C, et al. Podocan unraveled: Understanding its role in tumor proliferation and smooth muscle regulation[J]. Biomed Pharmacother, 2024, 179: 117416.
[25] LI X C, ZHU X Y, WANG Y Y, et al. Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation[J]. Acta Pharmacol Sin, 2024, 45(9): 1861-1878.
[26] 孙小平, 邓扬嘉, 李佳俊, 等. PPARγ促进miR-16表达抑制脓毒症炎症反应的作用研究[J]. 第三军医大学学报, 2018, 40(2): 141-148.